<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>Puma Biotechnology: A Short Thesis For Investors [Pfizer Inc., GlaxoSmithKline plc (ADR), Roche Holding Ltd. (ADR)] - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

 <script type="text/javascript">
 window.qbaka || (function(a,c){a.__qbaka_eh=a.onerror;a.__qbaka_reports=[];a.onerror=function(){a.__qbaka_reports.push(arguments);if(a.__qbaka_eh)try{a.__qbaka_eh.apply(a,arguments)}catch(b){}};a.onerror.qbaka=1;a.qbaka={report:function(){a.__qbaka_reports.push([arguments, new Error()]);},customParams:{},set:function(a,b){qbaka.customParams[a]=b},exec:function(a){try{a()}catch(b){qbaka.reportException(b)}},reportException:function(){}};var b=c.createElement("script"),e=c.getElementsByTagName("script")[0],d=function(){e.parentNode.insertBefore(b,e)};b.type="text/javascript";b.async=!0;b.src="//cdn.qbaka.net/reporting.js";"[object Opera]"==a.opera?c.addEventListener("DOMContentLoaded",d):d();qbaka.key="697c30d6de0ec176f16bc61dacb2980d"})(window,document);qbaka.options={autoStacktrace:1,trackEvents:1};
 </script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Breaking News - Real-time stock market news updates' ,
  'http://seekingalpha.com/news/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Breaking News - Real-time stock market news updates ;action-uri=http://seekingalpha.com/news/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta property="fb:admins" content="100006791796236" />

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="Puma Biotechnology: A Short Thesis For Investors">
<meta name="twitter:description" content="
  Investment Thesis
Puma Biotechnology (PBYI) is an oncology focused biotech company. Its lead asset Neratinib is being developed in several programs, the most advanced being a Phase III in 2nd/3rd line HER2+ metastatic breast cancer. Based on the labels of targeted HER2+ therapies, the drug will compete amongst others with Tykerb. Both compounds are Tyrosine Kinase Inhibitors (TKIs) that block the HER2/EGFR pathways. Both are combined with Xeloda to treat the condition, and show the same serious toxicities, diarrhea and hand and foot syndrome. Given the side effects, physicians have limited use of Tykerb to patients that have few options. Importantly, toxicities associated with Neratinib in the salvage setting might be an issue in earlier disease trials where regulators have higher standards for safety. Although, PBYI has presented data demonstrating that prophylaxis Imodium given with Neratinib reduces diarrhea events to zero, the number of patients treated is">
<meta name='twitter:image' content='http://static.cdn-seekingalpha.com/images/users_profile/000/333/717/big_pic.png?1359069536'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Investment Thesis Puma Biotechnology (PBYI) is an oncology focused biotech company. Its lead asset Neratinib is being developed in several programs, the most" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NYSE:PBYI, NYSE:PFE, NYSE:GSK, OTCMKTS:RHHBY" /><meta name="news_keywords" content="PBYI, Puma Biotechnology Inc., GSK, GlaxoSmithKline, Healthcare, Short Ideas, Top Idea, United States, Biotechnology, Editors' Picks" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/2082803" /><meta name="original-source" content="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors"><meta name="proarticle" content="true" /><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="Puma Biotechnology: A Short Thesis For Investors" />
<meta property="og:description" content="Investment ThesisPuma Biotechnology (PBYI) is an oncology focused biotech company. Its lead asset Neratinib is being developed in several programs, the most advanced being a Phase III in 2nd/3rd line HER2+ metastatic breast c" />
<link rel="canonical" href="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors" />
<meta name='viewport' content='width=1240'>

<script>
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
</script>

<link href="http://static1.cdn-seekingalpha.com/stylesheets/packaged/performance_layout_packaged.css?1396870223" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/packaged/performance_layout_b_packaged.css?1396870224" media="screen" rel="stylesheet" type="text/css" /><link href="http://static3.cdn-seekingalpha.com/stylesheets/packaged/article_packaged.css?1396870224" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var siteon = false; var atest = true; var acounter = 0;</script>
<script type="text/javascript" src="/javascripts/siteon.js"></script>

<script type="text/javascript">
  var users_on_site='3,201,411';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();

  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script src="http://static3.cdn-seekingalpha.com/javascripts/packaged/common_packaged.js?1396860960" type="text/javascript"></script>
<script src="http://static2.cdn-seekingalpha.com/javascripts/packaged/common2_packaged.js?1396860964" type="text/javascript"></script><script src="http://static2.cdn-seekingalpha.com/javascripts/packaged/common_article_packaged.js?1396870216" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/memcached2/symbol_rt_data"></script>

<script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
  (function(){
    var url='/article/2082803-puma-biotechnology-a-short-thesis-for-investors';
    if (location.pathname!=url){
      if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
      else location.href=url+location.search;
    }
  })();
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

</script>


<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-5.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"c0370b1d43","applicationID":"334927,334928","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1D","queueTime":0,"applicationTime":73,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-378.min.js"}</script>
<script type="text/javascript">(window.NREUM||(NREUM={})).loader_config={xpid:"UwUUUlVXAQEH"};window.NREUM||(NREUM={}),__nr_require=function t(e,n,r){function o(i){if(!n[i]){var a=n[i]={exports:{}};e[i][0].call(a.exports,function(t){var n=e[i][1][t];return o(n?n:t)},a,a.exports,t,e,n,r)}return n[i].exports}for(var i=0;i<r.length;i++)o(r[i]);return o}({1:[function(t,e){function n(t,e,n){n||(n={});for(var r=i[t],o=r&&r.length||0,s=n[a]||(n[a]={}),d=0;o>d;d++)r[d].apply(s,e);return s}function r(t,e){var n=i[t]||(i[t]=[]);n.push(e)}function o(t){return delete t[a]}var i={},a="nr@context";e.exports={on:r,emit:n,clear:o}},{}],2:[function(t){function e(t,e,o,a,d){return s?s-=1:n("err",[d||new UncaughtException(t,e,o)]),"function"==typeof i?i.apply(this,r(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}var n=t("handle"),r=t(6),o=t(5),i=window.onerror,a=!1,s=0;t("loader").features.push("err"),window.onerror=e;try{throw new Error}catch(d){"stack"in d&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&t(4),a=!0)}o.on("fn-start",function(){a&&(s+=1)}),o.on("fn-err",function(t,e,r){a&&(this.thrown=!0,n("err",[r,(new Date).getTime()]))}),o.on("fn-end",function(){a&&!this.thrown&&s>0&&(s-=1)})},{1:5,2:4,3:3,4:6,5:1,6:14,handle:"D5DuLP",loader:"G9z0Bl"}],3:[function(t){function e(t){r.inPlace(t,["addEventListener","removeEventListener"],"-",n)}function n(t){return t[1]}var r=t(1),o=(t(3),t(2));if(e(window),"getPrototypeOf"in Object){for(var i=document;i&&!i.hasOwnProperty("addEventListener");)i=Object.getPrototypeOf(i);i&&e(i);for(var a=XMLHttpRequest.prototype;a&&!a.hasOwnProperty("addEventListener");)a=Object.getPrototypeOf(a);a&&e(a)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&e(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=e["nr@wrapped"]?t[1]=e["nr@wrapped"]:e["nr@wrapped"]=t[1]=r(e,"fn-"):"function"==typeof e.handleEvent&&r.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:15,2:1,3:14}],4:[function(t){var e=(t(3),t(1)),n=t(2);e.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=e(t[0],"fn-")})},{1:15,2:1,3:14}],5:[function(t){function e(t){var e=t[0];"string"==typeof e&&(e=new Function(e)),t[0]=n(e,"fn-")}var n=(t(3),t(1)),r=t(2);n.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",e)},{1:15,2:1,3:14}],6:[function(t){function e(){n.inPlace(this,i,"fn-")}var n=t(1),r=t(2),o=window.XMLHttpRequest,i=["onload","onerror","onabort","onloadstart","onloadend","onprogress","onreadystatechange","ontimeout"];window.XMLHttpRequest=function(t){var i=new o(t);return r.emit("new-xhr",[],i),n.inPlace(i,["addEventListener","removeEventListener"],"-",function(t,e){return e}),i.addEventListener("readystatechange",e,!1),i},window.XMLHttpRequest.prototype=o.prototype},{1:15,2:1}],7:[function(t){function e(){function e(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function n(t){var n=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;p>o;o++)t.removeEventListener(u[o],this.listener,!1);if(!n.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){n.status=t.status;var a=t.responseType,s="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,d=e(s);if(d&&(r.rxSize=d),this.sameOrigin){var f=t.getResponseHeader("X-NewRelic-App-Data");f&&(n.cat=f.split(", ").pop())}}else n.status=0;r.cbTime=this.cbTime,i("xhr",[n,r])}}}function r(t,e){var n=a(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}function o(t,e){return e}t("loader").features.push("xhr");var i=t("handle"),a=t(1),s=t(5),d=t(6),u=["load","error","abort","timeout"],p=u.length,f=t(2);t(3),t(4),d.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=n,this.ended=!1,this.xhrGuids={}}),s.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),d.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),d.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),d.on("send-xhr-start",function(t,n){var r=this.metrics,o=t[0],i=this;if(r&&o){var a=e(o);a&&(r.txSize=a)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof n.onload))&&i.end(n)}catch(e){}};for(var s=0;p>s;s++)n.addEventListener(u[s],this.listener,!1)}),d.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),d.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),d.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),d.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&d.emit("xhr-load-added",[t[1],t[2]],e)}),d.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&d.emit("xhr-load-removed",[t[1],t[2]],e)}),d.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),d.on("fn-end",function(t,e){this.xhrCbStart&&d.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&e()},{1:8,2:11,3:3,4:6,5:15,6:1,handle:"D5DuLP",loader:"G9z0Bl"}],8:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],D5DuLP:[function(t,e){function n(t,e){var n=r[t];return n?n.apply(this,e):(o[t]||(o[t]=[]),void o[t].push(e))}var r={},o={};e.exports=n,n.queues=o,n.handlers=r},{}],11:[function(t,e){function n(t){if(!t||"object"!=typeof t&&"function"!=typeof t)return-1;if(t===window)return 0;if(o.call(t,"__nr"))return t.__nr;try{return Object.defineProperty(t,"__nr",{value:r,writable:!0,enumerable:!1}),r}catch(e){return t.__nr=r,r}finally{r+=1}}var r=1,o=Object.prototype.hasOwnProperty;e.exports=n},{}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],G9z0Bl:[function(t,e){function n(){var t=c.info=NREUM.info;if(t&&t.agent&&t.licenseKey&&t.applicationID){c.proto="https"===f.split(":")[0]||t.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var e=d.createElement("script");e.src=c.proto+t.agent,d.body.appendChild(e)}}function r(){"complete"===d.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=window,d=s.document,u="addEventListener",p="attachEvent",f=(""+location).split("?")[0],c=e.exports={offset:i(),origin:f,features:[]};d[u]?(d[u]("DOMContentLoaded",o,!1),s[u]("load",n,!1)):(d[p]("onreadystatechange",r),s[p]("onload",n)),a("mark",["firstbyte",i()])},{handle:"D5DuLP"}],14:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=n},{}],15:[function(t,e){function n(t,e,n,r){function nrWrapper(){try{var a,s=i(arguments),d=this,u=n&&n(s,d)||{};o.emit(e+"start",[s,d,r],u)}catch(p){}try{return a=t.apply(d,s)}catch(f){try{o.emit(e+"err",[s,d,f],u)}catch(p){}throw f}finally{try{o.emit(e+"end",[s,d,a],u)}catch(p){}}}return t&&"function"==typeof t&&t.apply&&!t._wrapped?(e||(e=""),nrWrapper._wrapped=!0,nrWrapper):t}function r(t,e,r,o){r||(r="");var i,a,s,d="-"===r.charAt(0);for(s=0;s<e.length;s++)a=e[s],i=t[a],i&&"function"==typeof i&&i.apply&&!i._wrapped&&(t[a]=n(i,d?a+r:r,o,a,t))}var o=t(1),i=t(2);e.exports=n,n.inPlace=r},{1:1,2:14}]},{},["G9z0Bl",2,7]);</script>
<link rel='alternate' href='android-app://com.seekingalpha.webwrapper/http/seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors' />      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@sectors@';
  var article_sectors_themes = '@short-ideas@sa-a-rich@us@biotechnology@editors-picks@pro@healthcare@article@';
  var ratings_hash={};
  var ARTICLE_ID = 2082803;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "unlocked";
  var ARTICLE_IS_PRO = "true"
  var author_slug = "poonam-a-arora";
  var author_id = "41611";
  var pticker_for_ads = "pbyi";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  var isTranscript = false;
    var insight_article = false;
    var sector_name = "Healthcare";
    var sector_slug = "healthcare";
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

</script>

<script>var mone_article_tags = "{gsk,pfe,rhhby,pbyi};;;{healthcare};;;{short-ideas,sa-a-rich,us,biotechnology,editors-picks,investing-ideas,sa-pro-articles,sa-a-rich,sa-exclusive};;;{poonam-a-arora}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<a href="sa://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors">
  <div id="smart_banner" style="display: none">
    <div id="ipad_smart_banner_ios6" onclick="SA.DeepLink.open_ipad_app('smart_banner')"></div>
    <div id="ipad_smart_banner_ios7" style="display: none" onclick="SA.DeepLink.open_ipad_app('smart_banner')"></div>
  </div>
</a>

<script>
  if (SA.Utils.Env.isIPad)  {
    $('smart_banner').show();
    Mone.event('ipad', SA.Utils.unifiedPath(), 'smart_banner_shown');
    var iosVersion = SA.Utils.Env.iosVersion().round();
    if(iosVersion > 6) var ipadVersion = 7;
    else var ipadVersion = 6;
    if (ipadVersion == 7){
      $('ipad_smart_banner_ios6').hide();
      $('ipad_smart_banner_ios7').show();
    }
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
        $$("body")[0].addClassName('ipad_promotion')
      }
    });
    function doOnOrientationChange() {
      switch(window.orientation)
      {
        case -90:
        case 90:
          $('header').setStyle({'margin-top': '100px'});
          break;
        default:
          $('header').setStyle({'margin-top': '120px'});
      }
    }
    window.addEventListener('orientationchange', doOnOrientationChange);
    setTimeout(doOnOrientationChange ,20);
  }
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            SA.Utils.Ads.add({el:$('top_banner_728x90'), HadCreated:false, size:'728x90', delta: null, NotSticky: true, info:'http://ad.doubleclick.net/N6001/adj/sek.investing-ideas/short-ideas;sz=728x90;x=x;tile=1;d=investing-ideas;t=short-ideas;aid=2082803;d=investing-ideas;d=sectors;t=short-ideas;t=sa-a-rich;t=us;t=biotechnology;t=editors-picks;t=pro;t=healthcare;t=article;z=3;a=poonam-a-arora;cnt=7;cnt=21;cnt=20;pr=pbyi;s=gsk;s=pfe;s=rhhby;s=pbyi;'+dart_my_vocation_and_profiles()+'ord='+ord+'?', pos_key: '-ncpbs10k19iy'});
            SA.Utils.Ads.run();
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs" style="font-size: 14px">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs" style="font-size: 14px">My Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/news/all" sasource="headtabs" style="font-size: 14px">Breaking News</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='analysis'>
          <a href="http://seekingalpha.com/analysis/all" sasource="headtabs" style="font-size: 14px">Latest Articles</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='stocktalks'>
          <a href="http://seekingalpha.com/stocktalks/all" sasource="headtabs" style="font-size: 14px">StockTalk</a>
          <span class="navi_right_corner">|</span>
        </li>

        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs" style="font-size: 13px">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">529</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">451,553</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>

  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before pro_full_article_unlocked">
    <script>
      if( (window.screen.availWidth > 1260) || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) $('main_container').addClassName('ads_cont');
    </script>
   <div class='ads_left'>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600">
          </div>
        </div>
    </div>
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      <div id="" class="no_big_gaps_secondary_ads">
        <div id='article_top_info'>
    <a href='/author/poonam-a-arora' sasource='auth_header_pic'><img id='author_info_img' class="author_img" align="center" src="http://static.cdn-seekingalpha.com/images/user/commenter_gray_115x115.png"></a>
    <div class='info_content'>
      <div>
        <a class='author_name' href='/author/poonam-a-arora' id='author_info_name' sasource='auth_header_name'>Poonam A. Arora</a>      </div>
      <div><span class='author_desc'>Long/short equity, value, research analyst, biotech</span></div>
      <div>
        <a href='/author/poonam-a-arora' sasource='auth_header_profile' class="author_action">Profile</a><span class='sep'>|</span>
        <span class='author_action' onclick='Messaging.sendMessage("49b2wuol", "auth_header", "article")'>Send Message</span><span class='sep'>|</span>
        <span id='follow_btn' class="follow_button_author"></span>
        <span class='clicks'>(<span id='follow_clicks' class='follow_clicks_author'>41</span>)</span>
        <span style="position:relative">&nbsp;<span id="follow_loader" class="follow_loader_author" style="display:none"></span></span>
      </div>
      <div id="notify_favorite_authors" class="clicks fl cb" style="display: none">(You’ll be notified by email with new articles from your favorite authors.)</div>
      <div class='arr_up'></div>
    </div>
    <script>
      if (isTranscript)
        SA.Pages.Article.Follow.init('poonam-a-arora');
      var author_version = ABTest.identity%10;
      $('follow_btn').observe('click', function(event) {
        unlock = null;
        if(this.className == 'link follow') {
          Mone.event("auth_follow", "article_auth_header", "follow_author");
          if (author_version == 1) {
            SA.Models.SubscriptionModel.subscribe(34909, "newsletters", "email preferences", unlock, unlock);
          }
        }
        else if (this.className == 'link unfollow') {
          Mone.event("auth_follow", "article_auth_header", "stop_follow_author");
        }
      });

    </script>
</div>



      </div>
      <div id="top_author_details">
        <div id="article_header" class="article_content pro">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">Puma Biotechnology: A Short Thesis For Investors</span>
              </h1>
      <div id="article_info">
       
        <div class="article_info_pos">
          <a href='/dashboard/top-ideas/' sasource='alpharichicon' target='_blank'><div class='top_idea_icon cp'></div></a>
          <span>Mar. 12, 2014  5:00 AM ET</span>
          <span class='print_hide'>&nbsp;|&nbsp;</span>
          <span id='title_article_comments'></span>
              <span class="print_hide">
                <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/PBYI" title='Puma Biotechnology, Inc.' sasource='article_primary_about'>PBYI</a></span>,                 <span>Includes: </span><span id='about_stocks'><a href="/symbol/GSK" title='GlaxoSmithKline' sasource='article_about'>GSK</a>, <a href="/symbol/PFE" title='Pfizer Inc.' sasource='article_about'>PFE</a>, <a href="/symbol/RHHBY" title='Roche Holding Ltd ADR' sasource='article_about'>RHHBY</a></span>              </span>
          <span class="author_name_for_print">by: Poonam A. Arora</span>
          <span id="second_line_wrapper">
                              </span>
        </div>
        <div class="article_disclosure">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
        </div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>
      </div>
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div class="cleaner"></div>
            <div class="summary_content" id="summary_content">
    <p class="title"><strong>Summary</strong></p>
    <ul>
        <li>Lead asset Neratinib is not best in class or first in class. Significant Grade 3 or 4 diarrhea is a major side-effect.</li>
        <li>The drug carries the risk of class effect given it’s similarity to Tykerb that doctors use sparingly due to toxicities.</li>
        <li>Given that Neratinib in most indications will be 3rd or 4th to market, PBYI will find it challenging to promote the drug in a space dominated by Roche.</li>
        <li>Although, Neratinib is being studied as treatment for various types of HER2+ breast cancer, the clinical and regulatory pathway for most indications is unclear.</li>
        <li>I believe the class effect and toxicity risk associated with Neratinib are being overlooked in the stock’s current valuation. My PT of $86.27/share reflects an appropriate risk rate.</li>
    </ul>
  </div>

            <p><b>Investment Thesis</b></p><p><a href="http://www.pumabiotechnology.com/" rel="nofollow">Puma Biotechnology</a> (<a href='http://seekingalpha.com/symbol/pbyi' title='Puma Biotechnology, Inc.'>PBYI</a>) is an oncology focused biotech company. Its lead asset Neratinib is being developed in several programs, the most advanced being a Phase III in 2nd/3rd line HER2+ metastatic breast cancer. Based on the labels of targeted HER2+ therapies, the drug will compete amongst others with Tykerb. Both compounds are Tyrosine Kinase Inhibitors (TKIs) that block the HER2/EGFR pathways. Both are combined with Xeloda to treat the condition, and show the same serious toxicities, diarrhea and hand and foot syndrome. Given the side effects, physicians have limited use of Tykerb to patients that have few options. Importantly, toxicities associated with Neratinib in the salvage setting might be an issue in earlier disease trials where regulators have higher standards for safety. Although, PBYI has presented data demonstrating that prophylaxis Imodium given with Neratinib reduces diarrhea events to zero, the number of patients treated is small. Given <a href="http://www.prnewswire.com/news-releases/puma-biotechnology-announces-positive-pb272-neratinib-phase-ii-data-at-ctrc-aacr-san-antonio-breast-cancer-symposium-135315593.html" rel="nofollow">the small difference in PFS observed</a> with Neratinib treatment in Tykerb na&iuml;ve and Tykerb experienced patients, I believe there is an opportunity for stacked PFS by using Tykerb first as 3rd line, and following with Neratinib as 4th line treatment.</p><p>In the neo-adjuvant setting, Neratinib will potentially compete with Perjeta and Tykerb. PBYI management has indicated plans that might include a fourth agent in the Neratinib based regimen as compared to three agents used in Perjeta and Tykerb based routines. Although, pre-clinical work has shown that <a href="http://www.ascopost.com/issues/february-15-2012-supplement/expert-point-of-view-dual-her2-blockade-substantially-delays-disease-progression.aspx" rel="nofollow">combining more HER2 targeted therapies improves efficacy</a>, the risk of higher toxicities is real, and might unbalance the risk/benefit ratio, particularly given the troublesome diarrhea observed with Neratinib. In addition, for insurers to pay for an additional agent, the Neratinib based regimen will have to demonstrate best-in-class type effectiveness and side-effects profile.</p><p>The adjuvant setting represents the largest market opportunity for Neratinib. Data from the Phase III ExteNET study are expected in 1H14. In this indication, Neratinib is being developed as 2nd line therapy following a year of Herceptin treatment. This is a novel treatment paradigm not tested before and if Neratinib is successful as 2nd line therapy, the revenue generation capacity of the drug would change dramatically. However, the treatment continuum in the adjuvant setting will in my opinion shift to Perjeta + Herceptin + Docetaxel, so the point of patients being placed on Neratinib after one year of Herceptin is moot. Therefore, I believe that PBYI will ultimately evaluate Neratinib as 1st line adjuvant treatment. <a href="http://clinicaltrials.gov/ct2/show/NCT00878709?term=extenet&amp;rank=1" rel="nofollow">Average enrollment size in trials in the setting is between 2,500</a> to <a href="http://clinicaltrials.gov/ct2/show/NCT00490139?term=altto&amp;rank=1" rel="nofollow">8,000</a> patients and will require significant commitment in resources which might be difficult for a company of PBYI's size to provide.</p><p>I believe my Price Target will be reached sooner rather than later. In the near-term, the NSAPB study in which Imodium is used as prophylaxis will report out in 1H14. In my opinion, Imodium use will not eliminate the diarrhea, and shares will pull-back. If Neratinib does get approved, it will see penetration in niche indications and in conditions where patients have few options. In larger settings, such as in adjuvant HER2+ breast cancer, the drug will have limited market share. As the reality of the real market opportunity sinks in, PBYI shares will adjust to reflect the true value. As the stock at current levels is baking in positive data from trials reporting this year and an outsized market opportunity for Neratinib, upside risk is limited. In order to justify a $3.4 billion market cap, the drug has to generate $3.5 billion in revenues in 2025 (vs. my $2 billion). In fact, I believe there is opportunity for more downside from my Price Target.</p><p><b>Risks</b></p><p>The primary threat to my Price Target comes from the possibility that PBYI gets acquired in the near to medium term. Although a buy-out at current valuations is counter-productive to my short thesis, a company being acquired at premium valuations because of a less then rigorous vetting process is entirely possible and not unheard of.</p><p><b>Valuation</b></p><p>I derive a 1-year Price target of $86.27/share for PBYI based on my sum-of-the-parts analysis for Neratinib in six indications and a cash/share of ~$7.69. The total cash balance of ~$232 million includes <a href="http://finance.yahoo.com/news/puma-biotechnology-closes-138-million-154000175.html" rel="nofollow">$138 million raised in a secondary offering</a> in February and the <a href="http://wsw.com/webcast/cowen16/PBYI/" rel="nofollow">$9.8 million the company is eligible to receive from Pfizer</a> (<a href='http://seekingalpha.com/symbol/pfe' title='Pfizer Inc.'>PFE</a>) in 1Q14. I used <a href="http://wsw.com/webcast/cowen16/PBYI/" rel="nofollow">an outstanding share count of 30.1 million</a> in my valuation.</p><p>Presented below are my peak revenue estimates and value/share for Neratinib in 6 indications and the assumptions I made to reach them.</p><p><b>Neratinib: Sum-of-the-Parts Analysis<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13945081780443606-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13945081780443606-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b></p><p><i>Source: Poonam A. Arora Estimates</i></p><p><b>Neratinib: A Pipeline in a Drug</b></p><p>PBYI's lead asset <a href="http://www.pumabiotechnology.com/pb272_neratinib.html" rel="nofollow">Neratinib is an orally bio-available irreversible TKI</a> that binds to the HER2 receptor on the cell surface and thereby inhibits downstream signaling transduction events and cell cycle regulatory pathways, arrests the cell division cycle, and ultimately decreases cellular proliferation. A dual inhibitor, it also blocks the EGFR kinase and thus prevents the incessant multiplication of cancer cells.</p><p><b>Puma Biotechnologies: Drug Development Pipeline</b></p><p><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944629994815187-Poonam-A--Arora.png" hspace="6" vspace="6" /></p><p><i>Source: Puma Biotechnologies Corporate Presentation March 2014</i></p><p>The primary focus of Neratinib development is on HER2+ metastatic breast cancer, neo-adjuvant HER2+ breast cancer, and adjuvant HER2+ breast cancer. The drug has the best possibility to secure regulatory approval in these indications. Additional conditions the drug is being studied in but which represent smaller market opportunities include HER2- mutated breast cancer, HER2+ advanced breast cancer with brain metastases, and HER2 mutated non-small cell lung cancer (NSCLC). See below for my revenue estimates for Neratinib from 2015 to 2025.</p><p><b>Puma Biotechnologies: Revenue Forecast 2015-2025 ($ in millions)<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394508247046473-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394508247046473-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b></p><p><i>Source: Poonam A. Arora Estimates</i></p><p><b>Neratinib in HER2+ Metastatic Breast Cancer</b></p><p>HER2 directed therapies commercially available for metastatic HER2+ breast cancer include Herceptin, Perjeta, Kadcyla, and Tykerb. Herceptin + Perjeta + Docetaxel is standard of care in 1st line HER2+ metastatic breast cancer. Although Tykerb + Xeloda is approved for 2nd line treatment, most doctors prefer to <a href="http://www.kantarhealth.com/blog/gordon-gochenauer/gordon-gochenauer/2012/06/03/Roche_Genentech_Magic_Bullet_in_HER2_Breast_Cancer" rel="nofollow">re-challenge with Herceptin + chemotherapy</a> than treat with Tykerb + Xeloda as the therapy is highly toxic. Instead, Tykerb + Xeloda is used as 3rd line treatment. Kadcyla, approved early last year for treating patients that have relapsed on other therapies appears <a href="http://www.ascopost.com/issues/february-15,-2013/treatment-of-her2-positive-disease-in-2013.aspx" rel="nofollow">set to become 2nd line standard of care for the condition</a>. As Neratinib + Xeloda is being developed as treatment for HER2+ metastatic breast cancer patients that have failed two HER2 targeted therapies, the combination will compete directly with Tykerb and Kadcyla.</p><p><b>Neratinib and Tykerb</b></p><p><a href="http://en.wikipedia.org/wiki/Lapatinib" rel="nofollow">Tykerb is similar to Neratinib in that it is a small molecule dual TKI</a> that blocks the activity of the HER2 and EGFR receptors on the cell surface. The drug interferes with HER2 and EGFR signaling by binding to the ATP pocket of the EGFR/HER2 proteins, preventing self-phosphorylation, and the subsequent activation of the signaling mechanism. It is FDA approved for treating HER2+ metastatic breast cancer patients that have progressed on treatments that included Herceptin, taxane chemotherapy, and an anthracycline. Neratinib and Tykerb can be compared on the basis of data from the Tykerb pivotal study and the Neratinib Phase II study, studies in which both drugs were given in combination with Xeloda.</p><p><b><a href="http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/24_MeetingAbstracts/P1-12-09" rel="nofollow">Results from Phase II Trial of Neratinib + Xeloda</a></b></p><p>Enrollment in the trial consisted of HER2+ metastatic breast cancer patients (n=72) that had all previously received Herceptin + taxane chemotherapy and 7 patients that had also received Tykerb. Patients received a combination of 240 mg Neratinib given daily from day 1 through 21 and Xeloda given daily at 1500 mg/m^2 from day 1 through 14 for each cycle. The primary end-point for the study was objective response rate defined as the percentage of patients that had complete response or partial response.</p><p>Among the group that had not previously been treated with Tykerb, 7 patients (~11%) experienced a complete response, 32 patients (~52%) achieved a partial response, and 5 patients (~8%) demonstrated stable disease for &gt;6 months, which represented an objective response rate of ~64% and a clinical benefit rate of ~72%. Among patients that were Tykerb experienced, 1 patient (~14%) achieved a complete response, 3 patients (~43%) experienced a partial response, and 1 patient (~14%) demonstrated stable disease for &gt;6 months. Median progression free survival &#40;PFS&#41; was 40.3 weeks and 35.9 weeks in the Tykerb experienced group and Tykerb naive group. The regimen was observed to be safe and tolerable with most frequently experienced adverse event &#40;AE&#41; being Grade 3 or 4 diarrhea observed in 26% of patients.</p><p>At the time of data cut-off for the planned interim analysis in June 2010, 8 patients (~11%) had withdrawn from the study due to AEs. In addition, 19 and 29 patients had their dose reduced, and 8 and 22 patients had their treatment interrupted because of side-effects. The most common drug-related AEs on Neratinib + Xeloda were diarrhea (89%), hand and foot syndrome (57%), nausea (33%), vomiting (26%), and decreased appetite (22%). Grade 3 or 4 side-effects included diarrhea (25%) and hand and foot syndrome (13%).</p><p><b><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727787/" rel="nofollow">Results from the Tykerb Pivotal Study</a></b></p><p>The Phase III trial enrolled women (n=324) that tested positive for HER2+ metastatic breast cancer who had failed treatment with Herceptin, taxane chemotherapy, and an anthracycline. Patients in the study were randomized 1:1 to receive either 1250 mg of Tykerb daily for 21 days + 2000 mg/m^2 of Xeloda from day 1 through 14 or a 2500 mg/m^2 dose of Xeloda alone from day 1 through 14. The primary end-point was time to tumor progression &#40;TTP&#41;. TTP was defined as time from randomization to tumor progression or death related to breast cancer.</p><p>Based on the recommendations of an independent data monitoring committee enrolment to the study was discontinued at the time of a pre-specified interim analysis, as the trial had met its primary end-point and had exceeded the predetermined stopping criteria. The trial was unblinded and patients on the Xeloda arm were allowed to cross over to Tykerb + Xeloda. <a href="http://www.prnewswire.com/news-releases/glaxosmithkline-seeks-us-approval-for-tykerbr-lapatinib-ditosylate-for-the-treatment-of-advanced-breast-cancer-57017747.html" rel="nofollow">At the time of interim analysis, the TTP of 36.7 weeks in the experimental arm was nearly double the 19.1 weeks observed in the control arm (p-value=0.00008).</a> After further follow-up, median TTP dropped to 27.1 weeks in the treatment group and 18.6 weeks in the comparator group (HR=0.57; p-value=0.00013). 23.7% of patients in the combination arm responded to therapy versus 13.9% in the monotherapy arm. Median overall survival &#40;OS&#41; reached 2 years after the efficacy analysis was 70 weeks on Tykerb + Xeloda and 65.9 weeks on Xeloda monotherapy.</p><p>The most common side-effects were diarrhea, hand and foot syndrome, nausea, and vomiting observed in 65%, 57%, 44%, and 26% of patients on the treatment arm versus 40%, 43%, and 21% observed in patients on the control arm. Grade 3 and 4 AEs were diarrhea and hand and foot syndrome experienced by 14% and 12% of patients on Tykerb + Xeloda and in 10% and 14% of patients on Xeloda alone. &lt;1% of patients suffered from Grade 3 and 4 hepatotoxicity for which the drug has a black box warning.</p><p><b>Comparison of Trial Data on Neratinib + Xeloda and Tykerb + Xeloda</b></p><p>The Neratinib + Xeloda regimen appears to be more effective on TTP and response rates than the Tykerb + Xeloda one. However, the Tykerb combination has a superior toxicity profile with respect to Grade 3 or 4 diarrhea at (14% vs. 26%) and hand and foot syndrome (12% vs. 13%). Physicians view key toxicities associated with Tykerb + Xeloda as troubling and limit use of Tykerb + Xeloda to the salvage setting. It is important to note, the strong data generated by Tykerb + Xeloda in the clinic and the combination's subsequent poor market performance as Neratinib and Tykerb belong to the same drug class. Therefore, the toxicity profile of Neratinib + Xeloda might be a gating factor for the agent's commercial success, if approved.</p><p>As median PFS in the Tykerb na&iuml;ve group was 40.3 weeks and that for the Tykerb experienced group was 35.9 weeks, it would be meaningful to place patients on Tykerb + Xeloda for a PFS of 27.1 weeks and then follow with Neratinib + Xeloda for another PFS of 35.9 weeks. Although, Neratinib + Xeloda appears to be more effective than Tykerb + Xeloda, the objective is to keep patients from progressive disease and death, in which case Tykerb + Xeloda until progression followed by Neratinib + Xeloda will provide superior clinical benefit. This would position, Neratinib + Xeloda as 4th line therapy for a majority of patients.</p><p><b>Neratinib and Kadcyla</b></p><p><a href="http://en.wikipedia.org/wiki/Trastuzumab_emtansine" rel="nofollow">Kadcyla is a HER2 targeted antibody drug conjugate</a> &#40;ADC&#41; comprised of Herceptin covalently bound with a stable linker to cytotoxic agent mertansine (DM1). The key advantage of the drug is that DM-1 is delivered only to cancer cells that express the HER2 protein thereby limiting toxicities observed with chemotherapy given as a separate agent. Kadcyla is approved in the US and Europe as treatment for HER2+ metastatic breast cancer in patients that had progressed on Herceptin and taxane chemotherapy. Therefore, on label use of the drug is possible in the 1st, 2nd, and even 3rd line metastatic settings. However, with Neratinib, Kadcyla will compete mostly in the 3rd line setting. The Phase III EMILIA study which formed the basis of the compound's approval and Neratinib Phase II study in HER2+ metastatic breast cancer provide data to compare the two drugs.</p><p><b><a href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124" rel="nofollow">Results from the Phase III EMILIA Study</a></b></p><p>The trial randomized 1:1 HER2+ metastatic breast cancer patients (n=991) to receive Kadcyla intravenously (IV) at 3.6 mg/kg of body weight on day 1 of a 21 day cycle or an oral combination of 1250 mg of Tykerb + 2000 mg/m^2 of Xeloda daily for 14 days. The co-primary end-points of the study were PFS, OS, and safety. Patients were treated with Kadcyla or Tykerb + Xeloda until progression of disease, withdrawal of consent, or unacceptable toxicity.</p><p>At 13 months of median follow-up, the median duration of treatment on Kadcyla, Tykerb, and Xeloda was 5.7 months, 4.9 months, and 4.8 months. Median PFS was 9.6 months on Kadcyla versus 6.4 months on Tykerb + Xeloda, representing a PFS benefit of 3.2 months (HR=0.65; p-value&lt;0.0001). Median OS was reached at 19 months of median follow-up and was 30.9 months in the treatment arm versus 25.1 months in the control arm (HR=0.68; p-value&lt;0.0003), representing an OS benefit of 5.8 months. Median duration of treatment was 7.6 months, 5.5 months, and 5.3 months for patients on Kadcyla, Tykerb, and Xeloda.</p><p>SAEs were observed in 15.5% of patients on Kadcyla and in 18% of patients on Tykerb + Xeloda. Grade 3 or 4 AEs were higher in the control group at 59% compared with 43% in the treatment group. Thrombocytopenia (14.5%), increased transaminases (8%), and fatigue (2%) on Kadcyla, and diarrhea (21%), vomiting (4.5%), and fatigue (3.5%) on Tykerb + Xeloda were the most experienced Grade 3 or 4 side-effects in the study. The most commonly reported AEs in patients on Kadcyla were thrombocytopenia (31%), nausea (40%) and increased transaminases (29%) versus diarrhea (80%) and rash (28%) observed in patients on Tykerb + Xeloda.</p><p><b>Comparison of Trial Data on Neratinib + Xeloda and Kadcyla</b></p><p>Neratinib + Xeloda is largely as effective as Kadcyla. Patients in both studies had progressed on Herceptin and taxane chemotherapy. Median PFS on Neratinib + Xeloda was 9.3 months versus 9.6 months on Kadcyla. 64% patients on Neratinib + Xeloda achieved objective response compared with 44% on Kadcyla. 11% of patients had withdrawn from the Neratinib + Xeloda study at time of interim analysis versus 7% of patients on Kadcyla. Dose interruptions and dose reductions were seen in 26% and 11% of patients on Neratinib + Xeloda and in 24% and 16% of patients on Kadcyla. An evaluation of outcomes from Neratinib's NALA study (expected in 2017) and Kadcyla's EMILIA trial will provide more color on the clinical competitiveness of the two agents.</p><p>Clearly the choice between Neratinib + Xeloda or Kadcyla will depend upon the physician's comprehension of each agent's toxicities and predictive factors. By the time results from the Phase III NALA study testing Neratinib in 2nd/3rd line setting are reported and the drug launched (if approved) in 2017, Kadcyla's efficacy and side effects profile will be clear and the drug entrenched in the market. In order to capture market share from Kadcyla, the Neratinib + Xeloda combination will need to demonstrate considerable superiority in efficacy and lower toxicities in the NALA trial.</p><p><b><a href="http://clinicaltrials.gov/show/NCT01808573" rel="nofollow">Pivotal Phase III NALA Study</a></b></p><p>Neratinib is currently being investigated in the Phase III NALA study as treatment for metastatic HER2+ breast cancer patients that have previously been treated with two or more HER2 targeted therapies. Patients (n=600) in this open label safety and efficacy trial are being randomized 1:1 to receive continuously daily for 21 days either a 240 mg oral dose of Neratinib or 1250 mg oral dose of Tykerb, both drugs given along with oral Xeloda 1500 mg/m^2 with Neratinib and 2000 mg/m^2 with Tykerb on day 1 to 14 of the 21 days cycle. The co-primary end-points of the study are PFS and OS. Patient enrollment for the study is currently ongoing. As per clinicaltrials.gov, estimated final data collection date for primary measure and study completion date are May 2017 and May 2018 respectively. PBYI management has reported plans to file for accelerated regulatory approval for Neratinib on basis of PFS data which could be available roughly a year following complete enrollment in the trial.</p><p><b>NALA Study Will Beat on End-Points, Could Stumble on Safety Outcomes</b></p><p>In my view, the NALA study is derisked, given that Neratinib + Xeloda beat Tykerb + Xeloda on PFS in the Phase II part of the study. OS data was not available for Neratinib + Xeloda in the trial and Tykerb + Xeloda demonstrated a median OS of 16.1 months in the Tykerb pivotal study. Neratinib + Xeloda will have to beat Tykerb + Xeloda on OS in NALA. It is important to note that TTP on Tykerb + Xeloda dropped on further follow-up after the pivotal trial was stopped early for efficacy. In my opinion, the primary data to watch for in the NALA trial will be on toxicities and longer term treatment durability. Grade 3 or 4 diarrhea and hand and foot syndrome were observed on Neratinib + Xeloda in the Phase II part of the trial and could signal a class effect related to dual inhibition of the HER2 and EGFR kinases.</p><p><b>Neratinib Market Forecast and Value/Share (in HER2+ Metastatic Breast Cancer)</b></p><p>Given data that suggests a potential for stacked PFS, I believe Neratinib + Xeloda will for most cases be used as 4th line treatment after Tykerb + Xeloda, with limited penetration in 2nd and 3rd lines. In the U.S., <a href="http://seer.cancer.gov/statfacts/html/breast.html" rel="nofollow">the incidence of breast cancer was estimated to be 232,340 in 2013</a>. It is projected that 20% of breast cancer patients test HER2+ at time of initial diagnosis. In 2013, <a href="http://seer.cancer.gov/statfacts/html/breast.html" rel="nofollow">the prevalence of breast cancer in American women was 2,829,041</a>.</p><p>Assuming that 12.5% of women with HER2+ disease are metastatic at initial diagnosis, and 5% of a projected 15% of women living with metastatic breast cancer that advanced from early disease have HER2+ metastatic breast cancer, I derive a 1st line HER2+ metastatic breast cancer population. I assume the European market will be similar in size to that of the U.S. and that the treatment cost/cycle will be 25% lower than in the States.</p><p>Incorporating the data points mentioned above and projecting progression rates of 50%, 65%, and 80% from 1st line to 2nd line, 2nd line to 3rd line, and 3rd line to 4th line, penetration rates of 15%, 17.5%, and 60% in the 2nd line, 3rd line, and 4th line settings, a treatment cost/cycle of $5,697, and average duration of treatment of 9 months, I estimate peak global revenues of $448 million for Neratinib to PBYI in 2023 in the metastatic setting. The treatment cost/cycle is comparable to what GlaxoSmithKline (<a href='http://seekingalpha.com/symbol/gsk' title='GlaxoSmithKline'>GSK</a>) is charging for Tykerb.</p><p>Integrating the revenue estimate, assuming a sales multiple of 6, a possibility of approval of 65%, and a discount rate of 15%, I arrive at $14.34/share value for the agent.</p><p><b>Neratinib: Global In-Market Sales Forecast in HER2+ Metastatic Breast Cancer<br><em>(click to enlarge)<br><em><a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944636444343467-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944636444343467-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Neratinib in Neo-Adjuvant HER2+ Breast Cancer</b></p><p>The term neo-adjuvant in breast cancer is used to describe a setting prior to surgery. Neo-adjuvant therapy is administered to patients in order to shrink their tumors before they are surgically removed. The standard of care for newly diagnosed HER2+ early breast cancer is Perjeta + Herceptin + Docetaxel. The FDA approved this regimen on the basis of outcomes generated from the Phase II Neosphere study. Presently, the Phase III NeoALTTO trial is evaluating Tykerb + Herceptin + Paclitaxel in the same setting. Neratinib is being investigated as part of combination therapy in this setting in two studies: the I-SPY 2 trial which has completed Phase II evaluation of Neratinib + Paclitaxel, and a National Surgical Breast and Bowel Project (NSABP) study testing Neratinib + Herceptin + Paclitaxel. Neratinib will compete with Perjeta and Tykerb (if approved) in the neo-adjuvant setting.</p><p><b>Neratinib and Perjeta</b></p><p><a href="http://en.wikipedia.org/wiki/Pertuzumab" rel="nofollow">Perjeta is a HER dimerization inhibitor that disrupts HER2 ligand dependent activation.</a> The drug has a complementary and distinct mechanism of action with Herceptin as the two compounds bind to different epitopes of the HER2 ectodomain and thereby provide more comprehensive inhibition. Results from the Perjeta's Neosphere study and several trials testing Neratinib + Paclitaxel with or without Herceptin can provide insight on the clinical and commercial competitiveness of the two drugs.</p><p><b><a href="http://investor.pumabiotechnology.com/press-release/puma-biotechnology-reports-positive-top-line-data-i-spy-2-trial" rel="nofollow">Results from the I-SPY 2 Study</a></b></p><p>The I-SPY 2 trial is a Phase II randomized study enrolling women with stage II or higher breast cancer in the neo-adjuvant setting. The study is being run to investigate the benefit of adding investigational agents to standard chemotherapy as treatment for certain bio-marker signatures driven breast cancer. The primary end-point is pCR in the breast and lymph nodes at the time of surgical resection.</p><p>In the study, Neratinib was administered in combination with Paclitaxel to 115 women, 65 of whom were HER2+ including those that were either hormone receptor &#40;HR&#41; positive or negative. The Neratinib + Paclitaxel regimen was tested against Herceptin + Paclitaxel. The Neratinib containing regimen graduated from the Phase II part of the study based on a high probability of success in a Phase III study with a signature of HER2+/HR negative. For HER2+ patients in the Neratinib + Paclitaxel group, pCR rates were higher than those observed with the Herceptin + Paclitaxel group, with a p-value of 0.047. Safety results were not reported by the company and are expected to be presented along with more details on efficacy at scientific meetings this year.</p><p>Based on Phase II outcomes, Neratinib is eligible for the I-SPY 3 Phase III study, which if run with the regimens administered in the Phase II has a 72.5% probability (Bayesian) of demonstrating statistically superior difference in pCR between the treatment and control groups.</p><p><b><a href="http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT1-1-12" rel="nofollow">NSABP Phase II Study</a></b></p><p>The trial is an open label, randomized study enrolling women (n=126) with locally advanced HER2+ breast cancer. Patients are divided into three groups to receive 4 cycles of either Neratinib + Herceptin + Paclitaxel; or Neratinib + Paclitaxel; or Herceptin + Paclitaxel. Oral Neratinib 240 mg is to be given from day 1 through 28 in the Neratinib + Paclitaxel arm. The Neratinib dose is lowered to 200 mg in the triplet regimen. IV Herceptin is to be given weekly at 4 mg/kg loading dose and then 2 mg/kg for 4 weeks. Patients are to receive 80 mg/m^2 of IV Paclitaxel given on day 1, 8, and 15 of a 28-day cycle. The primary end-point is pCR in breast and axillary lymph nodes following the neo-adjuvant therapies. The co-secondary end-points include objective response rate and OS. Results from this study are expected to be released in 2014.</p><p>NSABP earlier ran a Phase I study with the same design as the above trial in the metastatic setting. In addition, Neratinib + Paclitaxel was evaluated in a Phase I/II study in HER2+ metastatic breast cancer patients. Data from these studies could be helpful to potentially identify possible outcomes and safety of the Neratinib + Herceptin + Paclitaxel regimen in the neo-adjuvant setting.</p><p><b><a href="http://www.ncbi.nlm.nih.gov/pubmed/24077916" rel="nofollow">Results from the NSABP Phase I Study</a></b></p><p>Enrollment in the study comprised of women (n=21) with HER2+ metastatic breast cancer that had previously been treated with HER2 targeted therapies as well as a taxane. Designed as a dose escalation study, the trial was run to identify the maximum tolerated dose &#40;MTD&#41; and to evaluate the safety and efficacy of Neratinib (120 mg to 240 mg/day oral) + Herceptin (4 mg/kg IV loading dose, followed by 2 mg/kg IV weekly) + Paclitaxel (80 mg/m^2 IV on days 1, 8, and 15 of a 28-day cycle).</p><p>The recommended Phase II dose of Neratinib was 200 mg/day. Most frequently occurring Grade 3 and 4 side-effects in the trial were diarrhea (38%), dehydration (14%), electrolyte imbalance (19%), and fatigue (19%). Grade 3 and greater diarrhea was eliminated in patients administered mandated diarrheal prophylaxis. An objective response was observed in 8 patients (38%) and clinical benefit was evident in 11 patients (52%). Median PFS was 3.7 months.</p><p><b><a href="http://www.nature.com/bjc/journal/v108/n10/full/bjc2013178a.html" rel="nofollow">Results from Phase I/II of Neratinib + Paclitaxel</a></b></p><p>The Phase I part of the study was a dose escalation trial run to determine the MTD dose of Neratinib + Paclitaxel in patients (n=8) with solid tumors. In Phase II, HER2+ metastatic breast cancer patients (n=102) that had received previous therapy for their disease were placed on 240 mg of oral Neratinib + IV Paclitaxel at 80 mg/m^2 on day 1, 8, and 15 of a 28-day cycle.</p><p>The median overall treatment duration was 47.9 weeks. Most common all Grade and Grade 3 and 4 AEs were diarrhea (92%, 29%), peripheral neuropathy (51% and 3%), neutropenia (50%, 20%), hair loss (40% and 0%), leucopenia (41% and 18%), anemia (37% and 8%), and nausea (34% and 1%). 3% of patients discontinued treatment due to side-effects (mouth ulceration, left ventricular ejection fraction reduction, and acute renal failure). Objective response rate was 77% in Tykerb experienced patients and median PFS was 57 weeks (13.1 months).</p><p><b><a href="http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970336-9/abstract" rel="nofollow">Results from Phase II Neosphere Study</a></b></p><p>Designed as an open label study, the trial enrolled operable, locally advanced, or inflammatory HER2+ breast cancer patients (n=417) that had not received prior treatment for their disease. Patients were randomized 1:1:1:1 to receive either Perjeta + Herceptin (Group A); or Perjeta + Herceptin + Docetaxel (Group B); or Perjeta + Docetaxel (Group C); or Herceptin + Docetaxel (Group D). Herceptin was given every 3 weeks at 8mg/kg (cycle 1) followed by 6mg/kg. The loading dose of Perjeta was 840mg followed by 420mg. Docetaxel was given at 75mg/m^2, and if tolerated, escalated to 100mg/m^2. The therapy in each group was given for 4 cycles. The primary end-point was pCR defined as the absence of invasive cancer in the breast and lymph nodes.</p><p>At 12 weeks of median follow-up, a statistically significant 17.8% improvement in pCR rates (39.3% vs. 21.5%; p-value=0.0063) was observed between the Perjeta + Herceptin + Docetaxel group and the Herceptin + Docetaxel group. 11.2% of women on Perjeta + Herceptin and 17.7% of women on Perjeta + Docetaxel achieved pCR. Most commonly occurring Grade 3 or 4 AEs in the Perjeta + Herceptin + Docetaxel group and the Herceptin + Docetaxel group were neutropenia (44.9% vs. 58.9%), febrile neutropenia (8.4% vs. 7%), and leucopenia (4.7% vs. 11.2%) commonly seen with Docetaxel treatment. Other toxicities seen most frequently in the two groups included diarrhea (33.6% vs. 45.8%), nausea (36.4% vs. 39.3%), hair loss (66.4% vs. 65.4%), and fatigue (27.1% vs. 26.2%).</p><p><b>Comparing Results from Neratinib Studies and Neosphere</b></p><p>As pCR is the FDA mandated primary end-point for studies evaluating compounds for neo-adjuvant HER2+ breast cancer, and the Neratinib studies presented here (except the I-SPY 2 study) do not have data on pCR, the only material insight gleaned is on safety. Diarrhea shows up as an ongoing concern with Neratinib. Other than pattern diarrhea, the other side-effects associated with Neratinib regimens vary from study to study. Therefore, safety remains inconclusive based on available data and needs to be monitored in ongoing studies. Perjeta + Herceptin + Docetaxel has lower cardio-toxicities than Herceptin + Docetaxel, which is important as cardiac related events have been persistent with Herceptin associated regimens. Cardio-toxicity is not a concern with Neratinib.</p><p>Outcomes on pCR from the NSABP Phase II study evaluating Neratinib + Herceptin + Paclitaxel will decide whether this combination is better than Perjeta + Herceptin + Docetaxel. As this will be the first study to report on pCR rates seen with Neratinib + Herceptin + Paclitaxel, the results will be noteworthy. The I-SPY 2 study demonstrated pCR benefit in favor of the Neratinib + Paclitaxel when compared with Herceptin + Paclitaxel. In addition, Imodium being used as prophylaxis with Neratinib is expected to lower diarrhea rates in the study, so that safety data will be key. Since diarrhea was eliminated in the NSABP Phase I study, the Phase II results on diarrhea could be confirmatory.</p><p>The design for the I-SPY 3 study which according to management will likely be reported in 1H14 will be important as the trial might serve as a pivotal study. It will be interesting to see whether the NSABP consortium repeats the patient population of the Phase II study or enriches for bio-markers based on outcomes seen in the trial. In addition, given that the standard of care in the neo-adjuvant setting is Perjeta + Herceptin + Docetaxel, the choice of compounds that will be combined with Neratinib in the Phase III study will also be vital. Management has hinted that the third agent in the control arm could be Perjeta or Tykerb and they might even add a fourth agent to the experimental arm. There is pre-clinical data that suggests that the combination of several HER2 inhibitors improves efficacy but conclusive data in humans is unavailable. It is likely that combining many HER2 inhibitors might reflect in higher toxicities and result in an unfavorable risk benefit ratio. There is also the element of insurer's balking at the costs associated with adding a fourth agent to the regimen. For payors to come onboard, data from a Neratinib pivotal study will have to be outstanding. If the outcomes of the study are moderately superior, it will be difficult to get reimbursed, and doctors will limit use of the treatment, even if it gets approved.</p><p><b>Neratinib and Tykerb</b><br> Given the concept of class effect, that the two compounds belong to the dual HER2/EGFR inhibitor class, and have shown similar toxicities, evaluating results from Tykerb studies to predict potential outcomes from Neratinib trials makes sense. In addition, in the neo-adjuvant setting, the Tykerb NeoALTTO study and the Neratinib NSAPB trial, both agents are being combined with Herceptin + Paclitaxel, and are up against the same control group, setting up a head-to-head comparison. Moreover, results from the NeoALTTO study provide a benchmark for potential outcomes required for clinical success of the NSAPB Phase II study.</p><p><b><a href="http://www.ncbi.nlm.nih.gov/pubmed/22257673" rel="nofollow">Results from the Phase III NeoALTTO Study</a></b></p><p>The trial was an open label, randomized study that enrolled 455 patients with invasive HER2+ breast cancer with tumors that were &gt;2cm in diameter that had not previously been treated. Patients were randomized at first to receive either oral daily Tykerb (1500 mg), or weekly intravenous Herceptin (loading dose 4 mg/kg, subsequent doses of 2 mg/kg), or daily Tykerb (1000 mg) + weekly Herceptin for 6 weeks. After week 6, weekly Paclitaxel (80 mg/m^2) was added to the three regimens for another 12 weeks. The groups were well balanced for HR and clinical lymph node status. pCR was the primary end-point and secondary end-points included PFS and OS, in the intent to treat population.</p><p>Among the total patients enrolled, 154 received Tykerb, 149 were placed on Herceptin, 152 were given the combination, and all received Paclitaxel. 51.3% of patients on the combination therapy achieved pCR versus 29.5% of patients on Herceptin + Paclitaxel, representing a pCR benefit of 21.1% (p-value=0.0001). No significant difference in pCR was recorded between the Tykerb and Herceptin groups. There was no statistically significant difference in objective response rates recorded between the Tykerb (74%), Herceptin (70.5%) and the combination (80.2%) at the time of surgery. Cardio-toxicity was not material. Overall, more Grade 3 or 4 toxicities (diarrhea, neutropenia, hepatic toxicity, and rash) were observed in groups that received Tykerb. Diarrhea (21.1% vs. 2% vs. 23.4%), hepatic toxicity (9.9% vs. 7.4% vs. 17.5%), rash (6.6% vs. 2.7% vs. 6.5%) and neutropenia (7.2% vs. 1.3%, vs. 14.3%) were the most frequently observed Grade 3 or 4 AEs in patients on the combination vs. Herceptin vs. Tykerb, all with chemotherapy. Hepatic toxicity was defined as increasing levels of liver enzyme concentrations.</p><p>Overall, pCR rates were higher in patients with hormone receptor negative tumors than those HR positive tumors, in all groups. The Tykerb dose in the combination arm was lowered to 750 mg from 1000 mg to reduce the occurrences of diarrhea. Interestingly, all Grade 3 or 4 neutropenia onset began after addition of Paclitaxel to the assigned regimens. More patients assigned to the Herceptin versus the Tykerb assigned groups (91.9% vs. 60.5% vs. 66.2%) completed therapy. 12, 2, and 18 patients in the combination arm vs. the Herceptin arm vs. the Tykerb arm permanently discontinued therapy due to hepatic dysfunction. In addition, the liver toxicities associated with Tykerb assigned arms were also reported as SAEs.</p><p><b>Comparing Results from the Neratinib Studies and NeoALTTO</b></p><p>The regimen in NSAPB Phase II study is Neratinib + Herceptin + Paclitaxel. The treatment in the NeoALTTO trial was Tykerb + Herceptin + Paclitaxel. The control arm in both studies is/was Herceptin + Paclitaxel. The NeoALTTO trial reported a pCR benefit of 21.5% in favor of Tykerb + Herceptin + Paclitaxel, and the I-SPY 2 study showed a pCR benefit in favor of Neratinib + Paclitaxel when compared with Herceptin + Paclitaxel (the exact magnitude has not been reported yet, although management hinted at 15%). It is important to note the nasty side-effects observed in the NeoAltto study because they might show up in the Neratinib pivotal trial in the neo-adjuvant setting, given the potential for class-effect. In that regards, diarrhea and neutropenia was significant in NeoALTTO and has been evidenced in trials evaluating Neratinib + Paclitaxel, and therefore can be a concern in the NSAPB Phase II study, although the addition of Imodium to the Neratinib arm might resolve the diarrhea. In the Phase I study that evaluated Neratinib + Herceptin + Paclitaxel in a metastatic setting most frequently occurring Grade 3 and 4 side-effects were diarrhea (38%), dehydration (14%), electrolyte imbalance (19%), and fatigue (19%). Grade 3 and greater diarrhea was eliminated in patients administered mandated diarrheal prophylaxis. Since, these safety data are from a metastatic setting where patients are relatively sicker, it is likely that safety results from NASPB Phase II study could be more favorable.</p><p>In order to be successful, the Neratinib + Herceptin + Paclitaxel arm in NSAPB Phase II study must demonstrate a better pCR benefit than the 21.5% seen with Tykerb + Herceptin + Paclitaxel in NeoALTTO, and the pCR must be superior to the pCR achieved by the comparator arm. In addition, diarrhea rates must be substantially lower than observed with the Neratinib regimens in other studies. Furthermore, other toxicities including hepatic dysfunction seen with Tykerb regimens, and hand and foot syndrome seen with Neratinib regimens in the metastatic setting should be manageable. Results are expected later this year and along with the trial design of the proposed I-SPY 3 study will provide a blue print for the clinical and regulatory pathway for Neratinib in the neo-adjuvant setting.</p><p><b>Neratinib Market Forecast and Value/Share (in Neo-Adjuvant HER2+ Breast Cancer)</b></p><p>In the U.S., the incidence of breast cancer was estimated to be 232,340 in 2013. It is projected that 20% of breast cancer patients test HER2+ at time of initial diagnosis. In addition, <a href="http://seer.cancer.gov/statfacts/html/breast.html" rel="nofollow">~90% of breast cancer is diagnosed in the early stage</a>. In 2013, the prevalence of breast cancer in American women was 2,829,041. Assuming that 5% of the prevalence population is living with HER2+ breast cancer, and 10% of that number is receiving neo-adjuvant therapy, and ~25% of women with newly diagnosed HER2+ breast cancer elect to receive neo-adjuvant treatment, I derive an addressable population for Neratinib in the setting.</p><p>I assume the European market will be similar in size to that of the U.S. and that the treatment cost/cycle will be 25% lower than in the States. Incorporating the data points mentioned above and projecting a penetration rate of 25%, a treatment cost/cycle of $5,943, and average duration of treatment of 3 months, I estimate peak global revenues of $199 million for Neratinib to PBYI in 2025 in the neo-adjuvant setting.</p><p>Integrating the revenue estimate, assuming a sales multiple of 6, a possibility of approval of 65%, and a discount rate of 15%, I arrive at $6.37/share value for the agent.</p><p><b>Neratinib: Global In-Market Sales Forecast in Neo-Adjuvant HER2+ Breast Cancer<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394463943474789-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394463943474789-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Neratinib in Adjuvant HER2+ Breast Cancer</b></p><p>Neratinib is being studied in the Phase III ExteNET study as adjuvant treatment for HER2+ breast cancer patients that have received Herceptin +/- chemotherapy for 1 year following surgical resection. It is important to note that results from the <a href="http://www.ascopost.com/issues/november-1-2012/one-year-of-trastuzumab-remains-the-standard-of-care-in-her2-positive-breast-cancer.aspx" rel="nofollow">Phase III HERA study (after 8 years of follow-up) demonstrated no statistical difference</a> in disease free survival between HER2+ breast cancer patients that received adjuvant Herceptin for 1 year or 2 years. The standard of care adjuvant therapy remains as 1 year of Herceptin following surgery. <a href="http://clinicaltrials.gov/show/NCT00878709" rel="nofollow">The ExteNET study is novel</a> in that it is the first trial evaluating an agent as 2nd line adjuvant therapy. According to clinicaltrials.gov, the trial was completed in November 2013. Results from the study are expected to be reported at a medical conference in 1H14.</p><p>ExteNET is a double blinded, randomized, placebo controlled study that is evaluating Neratinib as monotherapy in women with early stage HER2+ breast cancer whose tumor has been surgically removed and who have received 1 year of Herceptin. Patients (n=2842) in the study were randomized 1:1 to receive either Neratinib or placebo. The primary end-point is disease free survival.</p><p>There are several studies currently ongoing which are investigating compounds in the adjuvant setting for HER2+ breast cancer. However, these trials are testing the agents as 1 year therapies after surgery. Therefore, these drugs will not potentially compete with Neratinib in the adjuvant setting. <a href="http://clinicaltrials.gov/ct2/show/NCT01358877?term=perjeta+adjuvant&amp;rank=3" rel="nofollow">The first is the APHINITY study (n=4805)</a> which is evaluating Perjeta + Herceptin + Docetaxel. <a href="http://clinicaltrials.gov/ct2/show/NCT00490139?term=altto&amp;rank=1" rel="nofollow">The second is the ALTTO study (n=8381)</a> evaluating Tykerb + Herceptin + Paclitaxel. These trials are confirmatory studies for results observed in the neo-adjuvant setting with the assigned agents, and will also provide PFS and OS data. <a href="http://clinicaltrials.gov/ct2/show/NCT01966471?term=perjeta+adjuvant&amp;rank=1" rel="nofollow">The third study (n=2500) is evaluating a combination of Kadcyla + Perjeta</a>.</p><p>Since these agents will not potentially jockey for share with Neratinib in the adjuvant setting, evaluating the studies is futile. Importantly, the addressable market size and revenue opportunity in this indication is huge enough to require large studies.</p><p><b>Neratinib Market Forecast and Value/Share (in Adjuvant HER2+ Breast Cancer)</b></p><p>The market opportunity for adjuvant stage HER2+ breast cancer therapies is the largest when compared with other stages of the disease. This is because most patients with early disease will have their surgical resection followed by systemic therapy in the adjuvant setting.</p><p>In the U.S., the incidence of breast cancer was estimated to be 232,340 in 2013. It is projected that 20% of breast cancer patients test HER2+ at time of initial diagnosis. In addition, ~90% of breast cancer is diagnosed in the early stage. In 2013, the prevalence of breast cancer in American women was 2,829,041. Assuming that 5% of the prevalence population is living with HER2+ breast cancer, and 20% of that number is receiving adjuvant therapy, and ~60% of women with newly diagnosed HER2+ breast cancer elect to receive adjuvant treatment, I derive an addressable population for Neratinib in the setting.</p><p>I assume the European market will be similar in size to that of the U.S. and that the treatment cost/cycle will be 25% lower than in the States. Incorporating the data points mentioned above and projecting a penetration rate of 25%, a treatment cost/cycle of $5943, and average duration of treatment of 9 months, I estimate peak global revenues of $1,136 million for Neratinib to PBYI in 2025 in the adjuvant setting.</p><p>Integrating the revenue estimate, assuming a sales multiple of 6, a possibility of approval of 65%, and a discount rate of 15%, I arrive at $36.36/share value for the agent.</p><p><b>Neratinib: Global In-Market Sales Forecast in Adjuvant HER2+ Breast Cancer<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394464114615285-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394464114615285-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Market Opportunity and Valuation of Neratinib in Additional Indications</b></p><p><b>Neratinib Market Forecast and Value/Share in HER2- Mutated Breast Cancer</b></p><p>In the U.S., the incidence of breast cancer was estimated to be 232,340 in 2013. It is projected that 12% of breast cancer patients test HER2- at time of initial diagnosis. In 2013, the prevalence of breast cancer in America was 2,829,041.</p><p>Assuming that 10% of the prevalence population is living with HER2- breast cancer, and 2% of that number has mutated disease, and that <a href="http://wsw.com/webcast/cowen16/PBYI/" rel="nofollow">~2% of women with newly diagnosed HER2- breast cancer have mutations</a>, I derive an addressable population for Neratinib in the setting.</p><p>I assume the European market will be similar in size to that of the U.S. and that the treatment cost/cycle will be 25% lower than in the States. Incorporating the data points mentioned above and projecting a penetration rate of 40%, a treatment cost/cycle of $5943, and average duration of treatment of 9 months, I estimate peak global revenues of $133 million for Neratinib to PBYI in 2025.</p><p>Integrating the revenue estimate, assuming a sales multiple of 6, a possibility of approval of 65%, and a discount rate of 15%, I arrive at $4.26/share value for the agent.</p><p><b>Neratinib: Global In-Market Sales Forecast in HER2- Mutated Breast Cancer<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944643407106545-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944643407106545-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Neratinib Market Forecast and Value/Share in HER2+ Breast Cancer with Brain Metastases</b></p><p>In the U.S., the incidence of breast cancer was estimated to be 232,340 in 2013. Last year, 2,829,041 women in America were living with breast cancer (prevalence). It is projected that 20% of breast cancer patients test HER2+ at time of initial diagnosis and <a href="http://wsw.com/webcast/cowen16/PBYI/" rel="nofollow">33% of women with HER2+ advanced breast cancer will develop brain metastases</a>.</p><p>Integrating the 33% figure on brain metastases referenced above with the incidence and prevalence data on women with late stage HER2+ breast cancer and assuming a penetration rate of 40%, a treatment cost/cycle of $5,943, and average duration of treatment of 9 months, I estimate peak global revenues of $195 million for Neratinib to PBYI in 2025.</p><p>I assume the European market will be similar in size to that of the U.S. and that the treatment cost/cycle will be 25% lower than in the States. Integrating the revenue estimate, assuming a sales multiple of 6, a possibility of approval of 65%, and a discount rate of 15%, I arrive at $6.24/share value for the agent.</p><p><b>Neratinib: Global In-Market Sales Forecast in HER2+ Breast Cancer with Brain Metastases<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394464455853806-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-1394464455853806-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Neratinib Market Forecast and Value/Share in HER2+ Mutated NSCLC</b></p><p>There are roughly <a href="http://seer.cancer.gov/statfacts/html/lungb.html" rel="nofollow">225,000</a> and <a href="http://www.pfizer.com/files/news/esmo/lung_cancer_fact_sheet.pdf" rel="nofollow">400,000 new cases of lung cancer diagnosed in the U.S. and Europe every year</a>. In 2013, there were 399,431 Americans living with lung cancer. In addition ~80% of newly identified lung cancer is NSCLC of which <a href="http://wsw.com/webcast/cowen16/PBYI/" rel="nofollow">HER2 mutations are observed in 2% to 4% of cases</a>.</p><p>Assuming that 60% of patients living with lung cancer are suffering from NSCLC, and 1% of those patients have HER2 mutations, and 3% of the newly diagnosed HER2+ NSCLC is of the mutated variety, I arrive at a targeted population for Neratinib in the indication.</p><p>Integrating the elements discussed above, and modeling a penetration rate of 45%, a treatment cost/cycle of $5,943, and average duration of treatment of 9 months, I project peak global revenues for Neratinib of $344 million in 2025.</p><p>Incorporating the revenue estimate with a revenue multiple of 6, a 65% possibility of regulatory approval, and a 15% discount rate, I forecast a $11.01/share value for the drug.</p><p><b>Neratinib: Global In-Market Sales Forecast in HER2+ Mutated NSCLC<br><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944645668906085-Poonam-A--Arora_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13944645668906085-Poonam-A--Arora.jpg" hspace="6" vspace="6" /></a></em></b><br><i>Source: Poonam A. Arora's Estimates</i></p><p><b>Strong News Flow Expected in 2014</b></p><p>Neratinib is being studied in many programs and data from several of the ongoing studies are expected at medical conferences in 2014. I anticipate significant volatility in PBYI shares throughout the year.</p><p><b>Neratinib: Catalyst and Milestones</b><br><i><img src="http://static.cdn-seekingalpha.com/uploads/2014/3/10/333717-13945083516176918-Poonam-A--Arora.jpg" hspace="6" vspace="6" /><br>Source: Puma Biotechnologies Corporate Presentation March 2014</i></p><p><b>Conclusion</b></p><p>Two words &quot;diarrhea and class-effect&quot; are not being accounted for in the current valuation. After having evaluated trials which used Neratinib as monotherapy or in combination with other agents, the common theme is a less than clean side-effects profile. Although, it is possible that concomitant use of anti-diarrheal Imodium might resolve the diarrhea, we just will not know until larger studies confirm what has been observed in an extremely small patient population. Until the safety of Neratinib is clear, the risk should be accounted for in the valuation, particularly because Neratinib shares a class with Tykerb which has a nasty side-effects profile. In that regards, it is important to note that Tykerb in clinical studies appeared to be a great drug with its pivotal trial stopped early for efficacy. But with further follow-up, the TTP dropped from 36.7 weeks to 27.1 weeks, and the toxicity profile in practice is much worse than it was in the clinic. In addition, with respect to commercialization of Neratinib, PBYI will find it challenging to sell the drug in a market dominated by Roche (<a href='http://seekingalpha.com/symbol/rhhby' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) at every stage of the disease. That being said, in my valuation of Neratinib, I have used a broad possibility of approval of 65% for each indication, which is very aggressive for a Phase II asset. Moreover, despite using reasonable estimates and assumptions such as peak revenues of $2.03 billion in 2025, a discount rate of 15%, and a revenue multiple of 6, (plus cash/share), the Price Target I reached was $86.27/share. I believe there is opportunity for more downside from my Price Target.</p>
            <div id="article_source">Source: <a href="/article/2082803-puma-biotechnology-a-short-thesis-for-investors?source=cc">Puma Biotechnology: A Short Thesis For Investors</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. <span id="additional_business_disclosure" style="display:none">I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</span> <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <div id="article_follow_author_bottom" class="no_big_gaps_secondary_ads" style="display: none">
          <div id="author_message_above" class="fwb fs13 fl mt25">Want more from this author? </div><div id="author_message_above2" class="fs13 fl mt25">&nbsp;Follow and be the first to know when they publish.</div>
<div id='article_bottom_info'>
    <img id='author_info_img' class="author_img" align="center" src="http://static.cdn-seekingalpha.com/images/users_profile/000/333/717/big_pic.png?1359069536">
    <div class='info_content'>
      <div id="followContainerBtn" class="tc fl cp" style="height: 20px; background-color: #F87217; padding-right: 10px">
        <span class="pr">&nbsp;<span id="follow_loader" style="display:none"></span></span>
        <span id='follow_btn2' class="follow_button_author" style="position:relative; bottom: -2px; color: white !important"></span>
        <span class='author_name fwb pr' id='author_info_name' onclick="$('follow_btn2').click()" style="bottom: -2px">Poonam A. Arora</span>
      </div>
      <span class='clicks fl pr' style="top: 5px; left: 10px;">(<span id='follow_clicks' class='follow_clicks_author'>41</span> followers)</span>
      <div><span class='author_desc fl cb'>Long/short equity, value, research analyst, biotech</span></div>
      <div class="clicks fl cb mt3">(You’ll be notified by email with new articles from your favorite authors.)</div>
      <div class='arr_down'></div>
    </div>
    <script>
      var sub_test_version = parseInt(ABTest.identity / 10)%10;
      if (sub_test_version == 2 || sub_test_version == 3) {$('author_message_above').innerHTML = "Do you trust this author to give you good analysis?"}
      else if (sub_test_version == 4 || sub_test_version == 5) {$('author_message_above').innerHTML = "Is this author on the ball?"}
      else if (sub_test_version == 6 || sub_test_version == 7) {$('author_message_above').innerHTML = "Impressed by this author?"}
      else if (sub_test_version == 8 || sub_test_version == 9) {$('author_message_above').innerHTML = "Receive future articles by this author via email:"; $('author_message_above2').hide();}
      SA.Pages.Article.Follow.init('poonam-a-arora');

      $('follow_btn2').observe('click', function(event) {
        unlock = null;
        if (this.className == 'link follow') {
          Mone.event("auth_follow", "article_bottom", "follow_author");
          SA.Models.SubscriptionModel.subscribe(34909, "newsletters", "email preferences", unlock, unlock);
        }
        else if (this.className == 'link unfollow') {
          Mone.event("auth_follow", "article_bottom", "stop_follow_author");
        }
      });
    </script>
</div>
        </div>
          <div id="pro_form_article_container">
            <div id="pro_form_introduction"></div>
            <div id="pro_form_container" class="pro_form_container_style" style="display:none;">
  <div id='pro_form_main_title'>
    <img id="pro_form_main_title_img" width="527px" height="35px" src="/images/pro/pro_logo_headline.png" />
  </div>
  <div id="pro_form_before_regsiter" class="pro_form_before_regsiter">
    <div id='pro_form_secondary_title'>
      <strong>Seeking Alpha PRO helps fund managers:</strong>
    </div>
    <div>
      <ul id="pro_form_secondary_title_list">
        <li style="margin-bottom:6px;">Research new investment ideas</li>
        <li style="margin-bottom:16px;">Reduce risk</li>
      </ul>
    </div>
    <div id="pro_form_third_title"><label>Find out if PRO is right for you:</label></div>
    <form id="pro_contact_form" action="/account/pro/contact" method="post" onsubmit="return false;" style="margin-bottom:20px;">
      <div id="pro_form_user_inputs_container">
        <div class="user_input_space"><label>Full Name</label><input class="temp_contact_field" type="text" name="name" onkeydown="removeErrorMessage(this);"/><span id="name_error" name="name" class="pro_form_error_field" style="display:none"></span><br/></div>
        <div class="user_input_space"><label>Work Email</label><input class="temp_contact_field" type="text" name="email" onkeydown="removeErrorMessage(this);"/><span id="email_error" name="email" class="pro_form_error_field" style="display:none"></span><br/></div>
        <div class="user_input_space"><label>Phone</label><input class="temp_contact_field" type="text" name="phone" onkeydown="removeErrorMessage(this);"/><span id="phone_error" name="phone" class="pro_form_error_field" style="display:none"></span><br/></div>
        <div id ="fund_container" class="user_input_space"><label>Fund Name</label><input class="temp_contact_field" type="text" name="fname"/><br/></div>
        <div id="aum_container" class="user_input_last_space">
          <label style="padding-top: 0px;margin-top:-2px;">AUM</label>
          <select id="aum_select" class="temp_contact_field" name="aum" onchange="removeErrorMessage(this);">
            <option value="">Select AUM</option>
            <option value="$0-100k">$0-100k</option>
            <option value="100-500k">100-500k</option>
            <option value="500k-1M">500k-1M</option>
            <option value="1-10M">1-10M</option>
            <option value="10-50M">10-50M</option>
            <option value="50-100M">50-100M</option>
            <option value="100M+">100M+</option>
          </select>
          <span id="aum_error" name="aum" class="pro_form_error_field" style="display:none"></span>
          <br/>
          <span class="aum_full">(Assets under Management)</span>
          <br/>
        </div>
      </div>
      <input type="hidden" name="referrer" class="temp_contact_field" empty="Refferer Page" value="" />
      <input id="lead_source" type="hidden" name="leadSource" class="temp_contact_field" empty="LeadSource" value="" />
      <div style="display:none;" id="contact_error"></div>
      <div id="submit_container">
        <div style="width:150px;float:left;margin-right: 14px;" class="pro_blue_button" id="last_button" onclick="SA.Pages.Account.Pro.Promo.sendContact('errorsBesideDisplay', 'article')">
          Contact Me
        </div>
        <div>
          <p>We only use your contact details to reply to your request for more information.<br/>We do not sell the personal contact data you submit to anyone else.</p>
        </div>
      </div>
    </form>
  </div>
  <div style="display:none;" id="pro_form_thanks_container" class="pro_form_thank_you_line_height_style">
    <div id="pro_form_thanks_text_container">
      <span style="font-weight:bold;">Thank you for your interest in Seeking Alpha PRO</span><br/>
      <span>We look forward to contacting you shortly for a conversation.</span>
    </div>
  </div>
  <div id="pro_form_sign_in_container" style="display:none;">
    <label>Already subscribed to PRO? <a href="#" onclick="open_header_log_in_popup_lightbox('headtabs_login',''); return false;">Sign in here</a></label>
  </div>
</div>

<script>
  var show_additional_user_preferences = null;
  if (candidate_reasons = SA.Pages.Account.Pro.Promo.isUserProCandidate()) {
    $("aum_container").remove();
    if (!show_additional_user_preferences) {
      $("fund_container").className = "user_input_last_space";
    }
  }
</script>

          </div>
          <script>SA.Pages.Article.handleDisclosures();</script>
          <div class="arich_promobox cb" style="display:none">
          </div>
        <div id="content_follow_up" class="underbar">
            <div id="follow_wrap">
                <div id="article_rta_bottom_container">
                    <div id="insight_promo_bottom" class="rta_bottom" style="display:none">
    <a class="rta_bottom_lnk" href='/insight/wisdomtree/investing-income' sasource='article_bottom'>Read more on Dividend Investing &raquo;</a>
  </div>

<div id="first_portfolio_unit_ref" style="display: none"> <div>
  <table id="first_portfolio_unit" style="border-top: 1px solid #DDD; padding-bottom: 7px !important; padding-top: 4px;">
    <thead><tr><th class="fs12">Symbol</th><th class="tr fs12">Price</th><th class="tr fs12">% Chg</th><th></th><th class="tc fs12">Remove</th><th></th></thead>
    <tbody>
         <tr id="first_portfolio_unit_cell0" class="mb10">
        <td style="width: 25%"><input id="first_portfolio_symbol_input0" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price0" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change0" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button0" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell0')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell1" class="mb10 b-light-gray2">
        <td style="width: 25%"><input id="first_portfolio_symbol_input1" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price1" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change1" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button1" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell1')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
         <tr id="first_portfolio_unit_cell2" class="mb10">
        <td style="width: 25%"><input id="first_portfolio_symbol_input2" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price2" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change2" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button2" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell2')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell3" class="mb10 b-light-gray2">
        <td style="width: 25%"><input id="first_portfolio_symbol_input3" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price3" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change3" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button3" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell3')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
         <tr id="first_portfolio_unit_cell4" class="mb10">
        <td style="width: 25%"><input id="first_portfolio_symbol_input4" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price4" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change4" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button4" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell4')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell5" class="mb10 b-light-gray2">
        <td style="width: 25%"><input id="first_portfolio_symbol_input5" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price5" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change5" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button5" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell5')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
         <tr id="first_portfolio_unit_cell6" class="mb10">
        <td style="width: 25%"><input id="first_portfolio_symbol_input6" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price6" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change6" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button6" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell6')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell7" class="mb10 b-light-gray2">
        <td style="width: 25%"><input id="first_portfolio_symbol_input7" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price7" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change7" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button7" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell7')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
         <tr id="first_portfolio_unit_cell8" class="mb10">
        <td style="width: 25%"><input id="first_portfolio_symbol_input8" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price8" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change8" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button8" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell8')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell9" class="mb10 b-light-gray2">
        <td style="width: 25%"><input id="first_portfolio_symbol_input9" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
        <td style="width: 22%" id="first_portfolio_unit_symbol_price9" class="tr fs12">-</td>
        <td style="width: 20%" id="first_portfolio_unit_symbol_price_change9" class="tr fs12">-</td>
        <td style="width: 13%">&nbsp;</td>
        <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button9" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell9')"></span></td>
        <td style="width: 13%">&nbsp;</td>
        </tr>
    </tbody>
  </table>
</div>
<script>SA.Units.Portfolio.First_portfolio_unit.init('first_portfolio_symbol_input',10, 'article Register')</script>
</div>
<div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">529</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>



<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      451,553
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="portfolio_unit" style="display:none">
  <div id="portfolio_list_title" class="fwb fl mt3">PORTFOLIO</div>
<select id="portfolio_list" class="portfolio_list fl ml20" onchange="SA.Units.Portfolio.select(this)"></select>

<div class="cb"></div>

<table id="portfolio_table" class="portfolio_table fl mt20">
  <thead class="db pr"><tr><th class="symbol">Symbol</th><th class="tc" style="width: 735px"></th><th class="portfolio_unit_price">Alerts</th><th class="portfolio_unit_price">Price</th><th class="portfolio_unit_price">Chg</th><th class="portfolio_unit_price">% Chg</th></tr></thead>
  <tbody class="db" id="portfolio_table_body"></tbody>
</table>

<div class="cb"></div>

<div id="portfolio_stocks_container" class="fl mt20">
  <div class="fl pr">
    <input type="text" id="portfolio_stocks_input" class="add_stock_text" placeholder="example: GLD, GOOG" style="height: 18px;" />
  </div>
  <span id="portfolio_stocks_btn" class="portfolio_stocks_btn ml5" onclick="SA.Units.Portfolio.addStocks()">Add Stocks</span>
  <span id="portfolio_stocks_error" class="portfolio_stocks_error" style="display:none"></span>
</div>

<div class="cb"></div>  <div class="mt20"></div>
  <div id="recommendation_unit" style="display:none" class="fl w100">
  <div class="mt10 ml10"><div class="fwb fl">New!</div><div class="fl ml5">Follow these related stocks</div></div>
  <div class="cb"></div>
  <div id="recommendation_buttons" class="ml6 mb10"></div>
  <div class="cb"></div>
  <div class="roy-gray fs12 mt10 ml10 mb10">(Click to add stocks to your portfolio)</div>
</div></div>


<img src="http://nxist.appledashboard.com/cimages/ads_1.jpg" id="adsimage" width="0" height="0"/>

                </div>
                <div id="article_rta_middle_container" style="display:none">
                  <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         529
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">451,553</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

                </div>
                <div id='article_pro_bottom_branding'>
                    This is a Top Idea which you received exclusive early access to.<br />
                  <b><a href='/dashboard/pro' sasource='article_bottom_latest_pro'>View The Latest Top Ideas &raquo;</a></b>
                </div>
              <div id="article_tags" style="display:none">
                <div itemprop="articleSection" class="tagged_with">
                  <span class="tagged_with_label">Tagged: </span><a href='/analysis/investing-ideas/all' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/short-ideas' sasource='article_navigation'>Short Ideas</a>, <a href='/analysis/sectors/healthcare' sasource='article_navigation'>Healthcare</a>, <a href='/articles?filters=biotechnology' sasource='article_navigation'>Biotechnology</a>, <a href='/analysis/all/editors-picks' sasource='article_navigation'>Editors&#x27; Picks</a>, <a href='/analysis/all/top-ideas' sasource='article_navigation'>Top Idea</a>
                </div>
              </div>
              <div class="share_this_page_article_bottom">
                <div id="share_unit">
  <div class="fwb fl mt3">Share this article with a colleague</div>
  <div class="ml35 fl">

    <!-- Email -->
      <div class="share_button" style="overflow: visible;">
          <span class="email_this" onclick="email_story_to_friends('Article',2082803,'http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors')">
            <div class="email_button"></div>
          </span>
      </div>

    <!-- twitter -->
    <div  class="share_button">
      <span class="twitter_small" style="overflow:hidden">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-via="salphatrending" data-related="salphatrending" data-count="none">Tweet</a>
      </span>
    </div>

    <!-- facebook -->
    <div  class="share_button">
      <!--div class="fb-share-button" data-href="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors?source=facebook" data-type="button"></div-->
      <div class="fb-like" data-href="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors?source=facebook" data-layout="button" data-action="like" data-show-faces="false" data-share="false"></div>
    </div>

    <!-- Linked In -->
    <div class="share_button">
       <span id="linkedin_" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="none" data-onsuccess="linkedin_callback" data-url="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors?source=linkedin_share"></script></span>
    </div>

    <!-- Plusone  -->
    <div  class="share_button">
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" data-annotation="none" data-width="65" data-callback="plusone_callback" data-href="http://seekingalpha.com/article/2082803-puma-biotechnology-a-short-thesis-for-investors?source=gplus"></div></span></span>
    </div>

    <!-- print -->
    <div  class="share_button">
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
    </div>

  </div>

  <div class="cb"></div>

</div>
              </div>
              <div id="article_bottom_about" class="article_bottom_units"></div>
              <div id="more_by_auth" class="more_by_auth"></div>
              <div id="more_by_ticker" class="article_bottom_units"></div>
              <div id="temporary_place_holder" class="mt10"></div>
              <div class="cleaner"></div>
            </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
    </div>
    <div class="article_right_content">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
          <script>var page_ad_src = 'http://ad.doubleclick.net/N6001/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;aid=2082803;d=investing-ideas;d=sectors;t=short-ideas;t=sa-a-rich;t=us;t=biotechnology;t=editors-picks;t=pro;t=healthcare;t=article;z=3;a=poonam-a-arora;cnt=7;cnt=21;cnt=20;pr=pbyi;s=gsk;s=pfe;s=rhhby;s=pbyi;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div id="ads_stick">
      <div class="item banner300x600">
        <script>add_js_to_ad_call('http://ad.doubleclick.net/N6001/adj/sek.investing-ideas/short-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=short-ideas;aid=2082803;d=investing-ideas;d=sectors;t=short-ideas;t=sa-a-rich;t=us;t=biotechnology;t=editors-picks;t=pro;t=healthcare;t=article;z=3;a=poonam-a-arora;cnt=7;cnt=21;cnt=20;pr=pbyi;s=gsk;s=pfe;s=rhhby;s=pbyi;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
      </div>
        <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
      <script type="text/javascript">
        ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
      </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "PBYI";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


      

        <div id="article_sidebar" class="article_sidebar">
          <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
        </div>

        <div class="cleaner"></div>
        <div class="stickyad_wrapper">
          <div class="item banner300x250" id="article_dart_sticky"></div>
        </div>
      <script>
          SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/N6001/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;aid=2082803;d=investing-ideas;d=sectors;t=short-ideas;t=sa-a-rich;t=us;t=biotechnology;t=editors-picks;t=pro;t=healthcare;t=article;z=3;a=poonam-a-arora;cnt=7;cnt=21;cnt=20;pr=pbyi;s=gsk;s=pfe;s=rhhby;s=pbyi;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
      </script>
  </div>
  </div>
  <script>
  if($$('#ads_stick .banner300x600')[0]) new stickyAd('ads_stick',{remove_stick_top:400}).fixed_ads_init()
  </script>
  
    </div>
  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/18n3n" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/sitemap" sasource="footer">Sitemap</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2014 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    function setAD(){
      if($('fixed_banner160x600').select('iframe')[0]) return;
      NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
      SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/N6001/adj/sek.investing-ideas/short-ideas;sz=160x600;x=x;tile=3;d=investing-ideas;t=short-ideas;aid=2082803;d=investing-ideas;d=sectors;t=short-ideas;t=sa-a-rich;t=us;t=biotechnology;t=editors-picks;t=pro;t=healthcare;t=article;z=3;a=poonam-a-arora;cnt=7;cnt=21;cnt=20;pr=pbyi;s=gsk;s=pfe;s=rhhby;s=pbyi;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
      Mone.article_shown_left_ad = true;
    }
    if((window.screen.availWidth > 1260) || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) setAD();
  </script>
<script>
  var follow_version = ABTest.identity%10;
  Event.observe(window, 'scroll', check_positions);
  if (SA.Utils.SASource.match(/email/)) createCookie('camefromrta',true);
  SA.Utils.wrapBigTables('article_body');
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    SA.Pages.Article.primary = "pbyi";
    SA.Pages.Article.init({fullProSidebar: null});
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }

    var pagination_version = ABTest.identity%10;
    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && SA.Pages.Article.from_partner() && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      setTimeout("SA.Pages.Article.btb()",7000);
  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["gsk","pfe","rhhby","pbyi"],"primarySlug":"pbyi","dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
  if(SA.Utils.Env.isAndroid && $(fixed_banner160x600)){$(fixed_banner160x600).addClassName('android')}
  $$('#article_body>p').each(function(p){ if ((p.childNodes.length==1) && (p.firstChild.tagName=='STRONG' || p.firstChild.tagName=='B')) p.addClassName('title'); })
</script>
    <script src="http://static3.cdn-seekingalpha.com/javascripts/packaged/jspell_packaged.js?1396860979" type="text/javascript"></script>
<link href="http://static2.cdn-seekingalpha.com/stylesheets/packaged/footer_packaged.css?1396861008" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static1.cdn-seekingalpha.com/javascripts/sa.js");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static1.cdn-seekingalpha.com/javascripts/tops.js?1396773683");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css?t=1396870404')});

  if (SA && SA.Data && SA.Data.User && SA.Data.User.loggedIn() && SA.Data.User.email() && SA.Data.User.email().match(/@seekingalpha.com/)){
    try{$('user_settings_pop').children[0].insert("<li class='mt10'><a href='javascript:void(0)' onclick='switch_status()'>PRO ON / OFF</a></li>");}catch(e){}
  }

  function switch_status(){
    new Ajax.Request('/authentication/get_menu', {
      asynchronous:true,
      method:'get',
      onComplete: function(transport) {
        eval(transport.responseJSON.code);
      }
    });
  }

  try{
    if (!siteon) {
      $('header').outerHTML += '<div id="outage_message">Most of Seeking Alpha is currently unavailable due to scheduled maintenance. Most published articles are still available for viewing. We apologize for any inconvenience.</div>';
      $('user_settings_wrapper').hide();
      $('outage_message').style.top = document.viewport.getDimensions().height -48 + "px";
    }
  } catch(e){}
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static.cdn-seekingalpha.com/javascripts/packaged/footer_packaged.js?1396870220" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
  }
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>



<div style="display: none">
  <script>
    /* <![CDATA[ */
    var google_conversion_id = 976471699;
    var google_conversion_label = "yEDNCN3OkAoQk43P0QM";
    var google_custom_params = window.google_tag_params; //defined in google_conversion.js, footer package
    var google_remarketing_only = true;
    /* ]]> */
  </script>
  <script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js"></script>
</div>
    <div class="cleaner"></div>
  </body>
</html>
